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Approximately 5% of patients with non-small cell lungcancer (NSCLC) have tumors with translocations involv-
ing the anaplastic lymphoma kinase (ALK) gene. ALK-trans-
located NSCLCs are sensitive to ALK tyrosine kinase inhib-
itors (TKIs), and crizotinib—the first Food and Drug
Administration-approved ALK inhibitor—has demonstrated
an impressive rate of antitumor responses.1 Despite crizo-
tinib’s impressive initial response rate (60%), most patients
eventually progress and the reported median progression-free
survival does not exceed 10 months.
Initial efforts have been made to identify mechanisms
responsible for acquired resistance to crizotinib and other
ALK TKIs. To date, only three patient-derived samples
with ALK-translocated NSCLC and acquired resistance to
crizotinib have been reported.2– 4 In two cases, acquired
ALK mutations were identified (Table 1). In addition, a
patient with RANBP2-ALK inflammatory myofibroblastic
tumor resistant to crizotinib had an ALK mutation in
one-third of progressing tumors2 (Table 1). However, it is
unknown whether emergence of acquired mutations is the
main mechanism of resistance to ALK inhibitors in
NSCLC.
CASE REPORT, METHODS, AND RESULTS
A 61-year-old white man with a prior 9 pack-year
history of smoking and stage IV E13;A20 EML4-ALK-
translocated NSCLC achieved a partial response to crizo-
tinib 250 mg twice daily as part of clinical trial A8081001
(NCT00585195).1 After 8 months of therapy, new liver
metastases and a growing pleural effusion were detected.
Tissue sampling of both areas confirmed NSCLC with
adenocarcinoma histology. Crizotinib was discontinued
and the patient died of tumor-related progression 10
months from his first dose of crizotinib.
Tumor-derived RNA was isolated using standard
techniques; reverse transcribed into cDNA and sequenced
using the following primers: (1) 5-GTGCAGTGTTTAG-
CATTCTTGGGG-3 and 5-TCTTGCCAGCAAAGCAG-
TAGTTGG-3 to confirm EML4-ALK E13;A20 and (2)
5-GAGCCCTGAGTACAAGCTGAG-3 and 5-GCCT-
GTTGAGAGACCAGGAG-3 to cover the entire ty-
rosine kinase domain of ALK (NM_004304.3). The use of
tissue material for these studies was approved by the
Institutional Review Board of Beth Israel Deaconess Med-
ical Center.
Sequence of the cDNA from the postprogression liver
and pleural specimens confirmed E13;A20 EML4-ALK (data
not shown). The complete tyrosine kinase of ALK, spanning
exons 20 to 28, was sequenced and no mutations were
identified. In specific, the nucleotide regions corresponding to
amino acid positions L1152, C1156, F1174, and L1196 did
not contain sequence variations (Figure 1).
DISCUSSION
We report a case of ALK-translocated NSCLC with
acquired resistance to crizotinib without presence of ALK
kinase domain mutations in two postprogression speci-
mens. A compilation of all five patients with ALK-trans-
located tumors that have been reported to date after ac-
quired resistance to crizotinib shows that only 3 of 8
(37.5%) unique progressing tumors had ALK mutations
(Table 1). The paucity of the “gatekeeper” L1196M mu-
tation in these samples (1 of 8 tumors, 12.5%) is of interest
and contrasts to the more than 50% frequency of the
epidermal growth factor receptor “gatekeeper” T790M
mutation in erlotinib-/gefitinib-resistant NSCLCs. Other
mechanisms of resistance to crizotinib are likely as com-
mon as — or more common than—acquired mutations.
Indeed, activation of epidermal growth factor receptor
signaling has been reported as a “bypass” mechanism in
one crizotinib-resistant ALK-translocated NSCLC.3 An-
other mechanism of acquired pharmacokinetic resistance
to crizotinib is related to inadequate blood-brain barrier
penetration of this TKI.5
Unbiased reporting of positive and negative findings
in tumor specimens is of utmost importance to increase our
understanding of the frequency of ALK mutations and of
novel resistance mechanisms in crizotinib-resistant
NSCLCs. These data will allow the rationale development
of clinical trials and strategies to overcome resistance to
ALK TKIs.
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FIGURE 1. Sequence chromatograms of crizotinib-progressive tumor specimens. Representative sequences from cDNA iso-
lated from a liver metastasis and malignant pleural effusion are shown. Nucleotide areas corresponding to previously reported
anaplastic lymphoma kinase (ALK) mutations (L1152, C1156, F1174, and L1196) are highlighted in blue. No sequence varia-
tions were identified based on the ALK gene sequence (NM_004304.3; homo sapiens ALK mRNA).
TABLE 1. Patient-Derived Samples from Tumors with Acquired Resistance to the ALK TKI
Crizotinib
Tumor Type Site of Tissue ALK Mutation
Other Mechanisms
Identified Reference
E13;A20 EML4-ALK NSCLC Pleural fluid L1196M, C1156Y (both
in 1 specimen)
Not reported 4
RANBP2-ALK IMT Abdominal tumors
(pelvic, colon,
liver)
F1174L (pelvic tumor);
none (2 other
specimens)
Not reported 2
E13;A20 EML4-ALK NSCLC Liver None Not reported 2
E6;A20 EML4-ALK NSCLC Pleural fluid L1152R Activation of EGFR
signaling
3
E13;A20 EML4-ALK NSCLC Liver, pleural fluid None (two specimens) Not reported Current report
E20;A20 EML4-ALK NSCLC N/A N/A Poor CSF penetration
of crizotinib
(pharmacokinetic
resistance)
5
ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; EML4, echinoderm microtubule-associated protein-like 4; RANBP2,
RAN binding protein 2; IMT, inflammatory myofibroblastic tumor; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor
receptor; CSF, cerebrospinal fluid; N/A, not applicable.
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